At the clinical level, the CXCR4 overexpression has been reported in women with advanced endometrial cancer (EC); the antitumor activity of two CXCR4-targeted NPs in vitro, including either the C. diphtheriae (T22-DITOX-H6) or P. aeruginosa (T22-PE24-H6) toxin were tested by repeated subcutaneous administrated of both nanotoxins in an EC mouse model these nanotoxin-induced antitumoral effects were observed in vitro as well as in vivo by inducing apoptosis without any off-target toxicity. The gene discussed is CXCR4; the disease is endometrial cancer.